Story perspectives

New Blood Biomarkers Streamline Lung Cancer Treatment

10/11/2025

Summary

Story summary

A study in BMC Cancer finds that systemic inflammation biomarkers identify high tumor mutation burden in lung adenocarcinoma.
The study analyzes 72 blood samples and shows that the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio correlate with high TMB.
Lymphocyte-to-monocyte ratio is lower with high TMB.
The study presents these markers as a cost-effective alternative to whole-exome sequencing.
The findings suggest these biomarkers could streamline immunotherapy stratification and support clinical practice integration.

1 of 1

Story summary

A study in BMC Cancer finds that systemic inflammation biomarkers identify high tumor mutation burden in lung adenocarcinoma.
The study analyzes 72 blood samples and shows that the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio correlate with high TMB.
Lymphocyte-to-monocyte ratio is lower with high TMB.
The study presents these markers as a cost-effective alternative to whole-exome sequencing.
The findings suggest these biomarkers could streamline immunotherapy stratification and support clinical practice integration.